Periprosthetic joint infection (PJI) in shoulder arthroplasty remains a diagnostic and management conundrum. The reported infection rate after primary shoulder arthroplasty is just under 1%[@B1] and it is approximately 5% after primary reverse shoulder arthroplasty.[@B2] Treatment options include antibiotic treatment, irrigation and debridement, single-stage revision, two-stage revision, resection arthroplasty, and arthrodesis.[@B3][@B4][@B5][@B6][@B7][@B8][@B9] While there is no definitive standard of care for the treatment of infected shoulder arthroplasty, two-stage revision is often utilized in a similar fashion to the common practice in hip and knee PJI.[@B10][@B11][@B12][@B13][@B14] Placement of an antibiotic spacer may be a bridge to a definitive arthroplasty with a two-stage revision or a definitive management option for PJI. Stine et al.[@B15] showed that the use of an articulating spacer was a suitable definitive treatment option in some patients; however, others experienced persistent pain and limited function that led to reimplantation.

The topic of antibiotic spacer types has been well-studied in two-stage revision for hip and knee PJI. Recent analyses have suggested that dynamic spacers have improved functional outcomes and better soft tissue preservation when compared to static spacers.[@B16][@B17][@B18] Furthermore, the use of dynamic spacers in two stage-revision knee arthroplasty allows for increased range of motion throughout the treatment with the spacer leading to reduced bone loss and less muscle atrophy without any evidence of significant wear damage.[@B19] In shoulder PJI, there are two main categories of antibiotic spacers utilized in two-stage revisions: stemmed and stemless. The clinical differences between these two implant choices have not yet been studied. For the purpose of this study, any antibiotic spacer that had any cement that entered into the humeral canal was considered a stemmed implant while any implant that was formed by simply creating a sphere of cement that was placed into the joint cavity after debridement was considered stemless. The purpose of this study was to evaluate all patients who underwent antibiotic spacer placement and evaluate differences in outcomes between the stemmed and stemless implants.

METHODS
=======

The study was approved by the Institutional Review Board of Thomas Jefferson University Hospital (IRB No. 45 CFR 46.110; \#16D.594) and performed in accordance with the principles of the Declaration of Helsinki. Informed consent was waived as this was purely retrospective review without intervention. After approval from the Institutional Review Board, we performed a retrospective analysis of our institutional shoulder arthroplasty database between January 1, 2011 and December 31, 2013. This database identified all primary and revision shoulder arthroplasty cases defined by the International Classification of Diseases, ninth revision, clinical modification (ICD-9-CM) codes. The codes utilized were 79.31 (open reduction of fracture of humerus), 80.01 (arthrotomy for removal of a prosthesis without replacement), 81.80 (total shoulder arthroplasty), 81.81 (shoulder hemiarthroplasty), 81.82 (repair of recurrent dislocation of shoulder), 81.83 (other repair of shoulder, arthroplasty), 81.88 (reverse total shoulder arthroplasty), and 81.97 (revision joint replacement upper extremity). Direct chart review was then performed to identify the subpopulation of patients that underwent placement of an antibiotic spacer. Operative notes and postoperative radiographs were utilized to determine if the antibiotic spacer was stemmed ([Fig. 1](#F1){ref-type="fig"}) or stemless ([Fig. 2](#F2){ref-type="fig"}). Prefabricated implants were not utilized. All spacers were created with tobramycin and vancomycin. All stemless spacers were made by creating a spherical ball of cement that was placed in the joint space. Any antibiotic spacer that had any cement that entered into the humeral canal was considered a stemmed implant. All stemmed spacers were created by fashioning cement into the shape of a stemmed humeral implant, with or without placement of a central, pre-bent wire. Complete medical records were reviewed to determine the total operative time from skin incision to skin closure in each case as well as complications. Operative cultures were reviewed for identification of infecting organism(s). Postoperative clinic notes at 2, 6, and 12 weeks as well as the final clinic note in our electronic medical records were reviewed to determine whether or not patients underwent reimplantation, the timing of reimplantation, and final range of motion after reimplantation. At a minimum of 2 years of clinical follow-up, recurrence of infection and any future reoperations following reimplantation were determined.

Descriptive statistics were utilized to compare the two antibiotic spacer subpopulations. Differences in categorical variables were evaluated by comparison of z-scores of proportions while continuous variables were evaluated by Student paired *t*-tests. Preoperative variables compared between two spacer subpopulations were age, gender, body mass index (BMI), and age-adjusted Charlson Comorbidity Index (CCI).[@B20][@B21] The operative times of antibiotic spacer placement were then compared between the two groups. The rates of reimplantation (second stage of the two-stage revision) were analyzed. Finally, in patients who underwent reimplantation, range of motion in forward elevation was measured at the latest postoperative visit (minimum 6 months). This range of motion data was directly collected by the surgeon. All statistics were calculated with Microsoft Excel 2013 (Redmond, WA, USA).

RESULTS
=======

Retrospective review of our institutional shoulder arthroplasty database identified 37 patients who underwent antibiotic spacer placement over the study period. There were 22 stemless implants (59.5%) placed and 15 stemmed implants (40.5%). The stemless group had an average age of 70.9 ± 7.8 years (range, 54.6 to 84.7 years), was 45.5% male, had an average BMI of 29.1 ± 6.4 kg/m^2^ (range, 19.5 to 48.0 kg/m^2^), and had an average age-adjusted CCI of 4.2 ± 1.2 (range, 2 to 6). There were two intraoperative complications in the stemless group; both were nerve injuries with electromyography-proven radial nerve palsies that self-resolved within 6 months of surgery. The culture data from the stemless group revealed that 12 of 22 (54.5%) had positive cultures: four isolated *Propionibacterium acnes* (33%), three coagulase-negative Staphylococcus species (CNS, 25%), 2 methicillin-sensitive *Staphylococcus aureus* (MSSA, 16.7%), one *Enterococcus faecalis* (8.3%), one *Escherichia coli* (8.3%), and one with both MSSA and *P. acnes* (8.3%). In comparison, the stemmed group had an average age of 62.8 ± 8.4 years (range, 48.0 to 81.9 years; *p* = 0.006), was 40% male (*p* = 0.742), had an average BMI of 31.5 ± 8.3 kg/m^2^ (range, 21.5 to 47.6 kg/m^2^; *p* = 0.354), and an average age-adjusted CCI of 4.2 ± 1.7 (range, 2 to 8; *p* = 0.958). Operative time for the stemless group was 127.5 ± 37.1 minutes (range, 62 to 200 minutes) compared to 130.5 ± 39.4 minutes (range, 74 to 188 minutes; *p* = 0.820) in the stemmed group. There were no intraoperative complications in the stemmed group. The culture data from the stemmed group was available for 14 of 15 patients and revealed that 7 of 14 (50.0%) had positive cultures: four isolated *P. acnes* (57.1%) and three MSSA (42.8%) ([Table 1](#T1){ref-type="table"}).

In the entire antibiotic spacer population, 27 of 37 patients (73.0%) underwent revision to definitive arthroplasty. Within the stemless group, 15 of 22 of patients (68.2%) went on to 18 future surgeries (two spacer exchanges, 15 reverse shoulder arthroplasties, and one open reduction of a dislocated reverse shoulder arthroplasty with glenosphere exchange) at an average of 6.8 ± 8.5 months (range, 0.8 to 34.0 months) after the index spacer placement ([Table 2](#T2){ref-type="table"}). In those stemless patients who were converted to a revision arthroplasty, 14 of 15 (93.3%) had final range of motion data at an average follow-up of 23.2 ± 11.9 months (range, 6.0 to 44.5 months). These patients had an average forward elevation of 109° ± 23° (range, 70° to 150°). The operative time for definitive reimplantation after stemless spacer placement was 143 ± 42 minutes (range, 89 to 236 minutes). There were no intraoperative complications in reimplantation within the stemless group. Intraoperative cultures were drawn for 14 of 15 reimplantations in the stemless group with 3 of 15 (20.0%) having at least one positive culture: one had negative cultures, but *P. acnes* were found on gram stain (this patient had negative cultures at the index spacer placement), one grew *P. acnes* (this patient had *P. acnes* at the index spacer placement), and one grew CNS (this patient had negative cultures at the index spacer placement). The first of these patients was treated as contaminant, while the other two were treated with oral antibiotics for 6 weeks. None of these three patients had clinical evidence of infection postoperatively. One stemless patient underwent reoperation for a dislocated reverse shoulder arthroplasty at 6 weeks after reimplantation. This patient required an open reduction with glenosphere exchange. With the exception of one reoperation, no patient required future reoperation at an average follow-up of 3.6 ± 1.0 years (range, 1.5 to 5.2 years).

Within the stemmed group, 14 of 15 (93.3%) went on to 15 future surgeries (two spacer revisions, one resection arthroplasty, one long-stemmed hemiarthroplasty, four total shoulder arthroplasties, and seven reverse shoulder arthroplasties) with 12 of 15 (80.0%, *p* = 0.427) undergoing definitive reimplantation at an average of 2.4 ± 0.7 months (range, 0.7 to 4.4 months) after the index spacer placement ([Table 3](#T3){ref-type="table"}). In those stemmed patients who were converted to a revision arthroplasty, 8 of 12 (66.7%) had final range of motion data at an average follow-up of 18.8 ± 8.5 months (range, 6.4 to 35.8 months). These patients had an average forward elevation of 94° ± 43° (range, 30° to 150°; *p* = 0.300). The operative time for definitive reimplantation after stemmed spacer placement was 154 ± 70.1 minutes (range, 57 to 304 minutes; *p* = 0.653). There were three complications during reimplantation in the stemmed spacer group. One patient was found to have a dislocated reverse shoulder arthroplasty in the recovery room on postoperative radiographs at which point the patient was brought back to the operating room for closed reduction. Two patients were found to have atrophy and loss of contractility of the anterior and middle deltoid. One had a confirmed diagnosis of axillary nerve palsy on electromyography that self-resolved within 6 months, while the other refused electromyography and had an incomplete return of function. Intraoperative cultures were recorded for 11 of 12 reimplantations in the stemmed group with 3 of 11 (27.3%) having at least one positive culture. In these three patients, one grew *E. coli* (one colony in broth only; grew *P. acnes* at the index spacer placement) and two grew an unspecified bacillus species (both one colony in broth only; both were negative at the index spacer placement). These were all treated as contaminant without clinical evidence of infection postoperatively. Following reimplantation from a stemmed spacer, there were no further reoperations performed at an average follow-up of 4.0 ± 0.8 years (range, 2.4 to 5.2 years). There were no clinical reinfections in either the stemless or stemmed population.

DISCUSSION
==========

The role of two-stage revision in management of shoulder PJI has been well-described.[@B3][@B4][@B5][@B6][@B7][@B8][@B9] Spacer placement is a viable option either as a bridge to reimplantation or as a definitive treatment modality. In our study, over three quarters of patients went on to have revision arthroplasty while the rest retained the spacer as a definitive implant. In both groups, the infection was adequately treated as there were no clinical signs of recurrent infections. Additionally, there was only one reoperation after reimplantation (glenosphere exchange for a reverse shoulder arthroplasty at 6 weeks after reimplantation), and there was no statistical difference between the stemmed and stemless spacers in terms of eventual reimplantation.

In hip and knee PJI, recent analyses found improved functional outcomes and better soft tissue preservation of dynamic spacers when compared to static spacers.[@B16][@B17][@B18] Prior to this study, there has not been an analysis on the ideal antibiotic spacer design in shoulder PJI. One advantage of stemless spacers that we expected was reduced operative time since the implant can be made from the beginning of the case and is easily inserted in the joint. However, we found similar operative times for implantation of both designs. It is likely that the operative time of complex shoulder PJI cases is driven by a number of technical variables, such as ease of stem excision, and that the effect of spacer type is negligible. Additionally, operative time of reimplantation was similar between the groups. This suggests that both implant types equally maintained the joint space and both are equally easy to remove upon revision surgery. Finally, the similar range of motion data after definitive reimplantation suggests that the choice of a stemmed or stemless implant does not have a major impact on the final functional outcome. While neither group returned to full range of motion, they did achieve similar forward elevation to that previously described for revision of hemiarthroplasty to reverse total shoulder arthroplasty.[@B22][@B23]

There were five total complications in the entire study group, two with index stemless spacer placement and three with reimplantation after stemmed implant placement. These complications included four neurologic injuries and one reverse shoulder arthroplasty dislocation. There were 70 total surgeries performed in our entire population which gives a neurologic injury rate of 5.7%, three of which completely resolved and one of which incompletely resolved. The literature reports a rate of neurologic injury of 1% to 4.3% in anatomic total shoulder arthroplasty[@B24][@B25] and from 1.7% to 11.6% in reverse shoulder arthroplasty[@B26][@B27][@B28] with revision surgery being a risk factor for neurologic injury.[@B29] The rate of neurologic injury in our patient population is within the range we expected given the complex nature of these cases. Three of these neurologic deficits fully resolved while one partially resolved, consistent with previous reports of these injuries being stretch neuropraxias rather than transection injuries.[@B25][@B27] Regarding bacterial cultures at the time of reimplantation, all patients that had one or less positive culture at the time of reimplantation were treated as a contaminant while those with two or more positive cultures were treated as true positive cultures per the protocol described by Frangiamore et al.[@B30] The two patients that met this criteria of culture positivity at the time of reimplantation were given 6 weeks of postoperative antibiotics. There were no reinfections after reimplantation in this study.

The findings of this study must be considered in the context of the limitations. First, the majority of our patients went on to have revision arthroplasty, which did not allow us to further study the differences between stemmed and stemless spacers as a final treatment option. Also, we did not have sufficient patient reported outcomes to fully analyze functional differences. While similar outcomes in forward elevation may provide a general idea of functional level, the availability of other outcomes, such as patientspecific functional results, would have been more substantial. Additionally, this is a purely retrospective study and therefore we can only determine associative relationships rather than speculate on causality. These were also very complex patients from both medical and technical perspectives. Therefore, retrospective analysis of the details of their clinical course is difficult. In order to mitigate this weakness, all of the patient charts were reviewed directly in their entirety instead of simply relying on the institutional database. Finally, because this was a retrospective study, the patient numbers were set without power analysis. Therefore, the nonsignificant trend of a higher reimplantation rate in patients with stemmed spacers may simply be a result of an underpowered study rather than truly nonsignificant.

This study offers the first comparison between patients with stemmed antibiotic spacers and stemless antibiotic spacers in shoulder arthroplasty. The patient populations that underwent stemmed and stemless antibiotic spacer placement were statistically similar in complication rate, final reimplantation rate, operative time, and final active forward elevation. When analyzing all antibiotic spacers, over 70% were converted to revision arthroplasties, after which there was one reoperation and no clinical reinfections. The results of this study do not suggest superiority of either stemmed or stemless antibiotic spacers. Future prospective analysis may determine differences in outcomes not observed in this study.
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###### Comparison of Stemmed and Stemless Groups

![](cios-9-489-i001)

  Category                         Stemless (n = 22)         Stemmed (n = 15)          *p*-value
  -------------------------------- ------------------------- ------------------------- -----------
  Age (yr)^\*^                     70.9 ± 7.8 (54.6--84.7)   62.8 ± 8.4 (48.0--81.9)   0.006
  Body mass index (kg/m^2^)^\*^    29.1 ± 6.4 (19.5--48.0)   31.5 ± 8.3 (21.5--47.6)   0.354
  Charlson Comorbidity Index^\*^   4.2 ± 1.2 (2--6)          4.2 ± 1.7 (2--8)          0.958
  Sex (%)^†^                                                                           0.742
   Male                            45.5                      40.0                      
   Female                          54.5                      60.0                      
  Operative time (min)^\*^                                                             
   Index spacer                    127.5 ± 37.1              130.5 ± 39.4              0.820
   Reimplantation                  143 ± 42                  154 ± 70                  0.653
  Reimplantation (%)^†^            68.2                      80.0                      0.427
  Forward elevation (º)^\*^        109 ± 23 (70--150)        94 ± 43 (30--150)         0.300

Values are presented as mean ± standard deviation (range) or mean ± standard deviation.

^\*^Comparison of continuous variables calculated by two sample *t*-test with equal variance. ^†^Comparison of proportional variables calculated by two sample z-test for comparing proportions.

###### Surgical Variables for All Patients That Underwent Stemless Spacer Placement

![](cios-9-489-i002)

  Sex      Age (yr)   Diagnosis at time of spacer placement                Months to reimplantation   Surgery at reimplantation     Reoperation after reimplantation
  -------- ---------- ---------------------------------------------------- -------------------------- ----------------------------- ----------------------------------------------------
  Female   84.7       Chronically dislocating TSA for OA from OSH          NA                         NA                            NA
  Male     69.1       Infected RTSA for CTA from OSH                       36.1                       RTSA                          No
  Female   59.6       TSA for PTA with deep infection                      18.4                       2 Spacer revisions and RTSA   No
  Female   76.2       Infected RTSA for CTA from OSH                       NA                         NA                            NA
  Male     73.4       Infected primary TSA from OSH                        NA                         NA                            NA
  Male     73.5       Infected primary TSA from OSH                        NA                         NA                            NA
  Female   82.0       Infected HA for CTA from OSH                         51.7                       RTSA                          No
  Male     54.6       Infected TSA with multiple I&Ds from OSH             40.8                       RTSA                          No
  Male     62.6       Chronically dislocating RTSA for CTA from OSH        28.7                       RTSA                          No
  Female   68.8       Infected TSA for OA                                  54.1                       RTSA                          No
  Female   66.9       Infected HA for proximal humerus fracture from OSH   63.4                       RTSA                          Open reduction and glenosphere exchange at 6 weeks
  Male     72.7       Primary septic arthritis in setting of CTA           37.4                       RTSA                          No
  Female   75.1       Infected TSA with dislocated glenoid from OSH        58.5                       RTSA                          No
  Male     61.0       TSA with significant loosening and metallosis        49.2                       RTSA                          No
  Female   63.6       Chronically dislocating RTSA for CTA from OSH        32.3                       RTSA                          No
  Female   81.9       Nonunion of RTSA periprosthetic fracture             37.0                       RTSA                          No
  Female   63.9       Infected RTSA for fracture from OSH                  NA                         NA                            NA
  Male     71.5       TSA glenoid and humeral loosening                    41.4                       RTSA                          No
  Female   71.1       Chronically infected HA from OSH                     NA                         NA                            NA
  Female   71.2       Infected TSA for OA                                  40.8                       RTSA                          No
  Male     77.4       Infected RTSA for CTA from OSH                       59.9                       RTSA                          No
  Male     78.3       Chronically infected TSA from OSH                    NA                         NA                            NA

TSA: total shoulder arthroplasty, OA: osteoarthritis, OSH: outside hospital, NA: not applicable, RTSA: reverse total shoulder arthroplasty, CTA: cuff tear arthropathy, PTA: posttraumatic arthritis, HA: hemiarthroplasty, I&D: irrigation and debridement.

###### Surgical Variables for All Patients That Underwent Stemmed Spacer Placement

![](cios-9-489-i003)

  Sex      Age (yr)   Diagnosis at time of spacer placement                           Months to reimplantation   Surgery at reimplantation   Reoperation after reimplantation
  -------- ---------- --------------------------------------------------------------- -------------------------- --------------------------- ----------------------------------
  Female   70.1       Infected HA for proximal humerus fracture from OSH              NA                         NA                          NA
  Male     48.0       Infected HA for RA from OSH                                     3.5                        Long stem HA                No
  Male     57.6       Infected HA for CTA from OSH                                    1.9                        RTSA                        No
  Female   61.7       Loosening of HA for proximal humerus fracture from OSH          1.2                        RTSA                        No
  Female   62.9       Infected HA for proximal humerus fracture from OSH              3.5                        RTSA                        No
  Male     60.3       Infected TSA and rotator cuff tear from OSH                     3.7                        RTSA                        No
  Female   60.0       Septic arthritis after arthroscopic debridement from OSH        1.2                        RTSA                        No
  Male     57.7       Primary septic arthritis from injection with I&D at OSH         0.9                        RTSA                        No
  Female   70.8       Chronic osteomyelitis after open acromioplasty at OSH           0.7                        RTSA                        No
  Female   64.1       Infected HA for proximal humerus fracture from OSH              NA                         NA                          NA
  Female   65.7       Glenoid and humeral loosening of TSA from OSH--Nickel allergy   3.6                        Nickel free TSA             No
  Female   51.7       Glenoid and humeral loosening of TSA from OSH--Nickel allergy   2.3                        Nickel free TSA             No
  Female   70.8       Painful HA with glenoid wear from OSH--elevated ESR/CRP         1.4                        TSA                         No
  Male     59.4       Osteomyelitis after rotator cuff repair from OSH                4.4                        TSA                         No
  Male     81.9       TSA with glenoid erosion from OSH                               NA                         NA                          NA

HA: hemiarthroplasty, OSH: outside hospital, NA: not applicable, RA: rheumatoid arthritis, CTA: cuff tear arthropathy, RTSA: reverse total shoulder arthroplasty, TSA: total shoulder arthroplasty, I&D: irrigation and debridement, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein.
